Through antagonistic action on the A2A receptor, chronic administration of CBZ suppresses the activation of astroglial glutamatergic transmission induced by proinflammatory cytokines Interferon-gamma (IFNγ) and tumor necrosis factor-alpha (TNFα), implying the benefits of CBZ in the prevention of pathomechanisms development in several neuropsychiatric disorders, such as Niemann–Pick disease, schizophrenia, and autism (Okada et al., 2019). This evidence concerns the gene TNF and Niemann-Pick disease.